SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Medtronic plc (MDT) trades at a trailing P/E of 24.4, forward P/E of 15.6. Trailing earnings yield is 4.09%, forward earnings yield 6.43%. PEG 0.27 (Peter Lynch undervalued ≤1.0). Graham Number is $55.74.
Criteria proven by this page:
- VALUE (47/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 15.6 (down from trailing 24.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.27 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.09% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 6.43% as earnings recover.
- Analyst consensus target $111.45 (+26.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 69/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
47/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MDT
Valuation Multiples
P/E (TTM)24.4
Forward P/E15.6
PEG Ratio0.27
Forward PEG0.27
P/B Ratio2.30
P/S Ratio3.18
EV/EBITDA14.9
Per Share Data
EPS (TTM)$3.60
Forward EPS (Est.)$5.67
Book Value / Share$38.37
Revenue / Share$27.68
FCF / Share$4.22
Yields & Fair Value
Earnings Yield4.09%
Forward Earnings Yield6.43%
Dividend Yield3.23%
Graham Number$55.74
SharesGrow IV$119.62 (+35.7%)
Analyst Target$111.45 (+26.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
31.5 |
10.99 |
2.15 |
3.87 |
1.92% |
| 2017 |
28.7 |
1.75 |
2.30 |
3.89 |
2.06% |
| 2018 |
35.0 |
-1.62 |
2.14 |
3.63 |
2.29% |
| 2019 |
25.8 |
0.51 |
2.39 |
3.91 |
2.25% |
| 2020 |
27.8 |
7.36 |
2.62 |
4.60 |
2.17% |
| 2021 |
48.8 |
-1.96 |
3.42 |
5.85 |
1.77% |
| 2022 |
27.8 |
0.70 |
2.67 |
4.42 |
2.41% |
| 2023 |
32.2 |
-1.31 |
2.35 |
3.87 |
2.99% |
| 2024 |
28.8 |
-13.58 |
2.11 |
3.27 |
3.46% |
| 2025 |
23.2 |
0.75 |
2.25 |
3.23 |
3.32% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$3.54 |
$28.91B |
$4.79B |
16.6% |
| 2021 |
$2.66 |
$30.12B |
$3.61B |
12% |
| 2022 |
$3.73 |
$31.69B |
$5.04B |
15.9% |
| 2022 |
$3.73 |
$31.69B |
$5.04B |
15.9% |
| 2023 |
$2.82 |
$31.23B |
$3.76B |
12% |
| 2023 |
$2.82 |
$31.23B |
$3.76B |
12% |
| 2024 |
$2.76 |
$32.36B |
$3.68B |
11.4% |
| 2024 |
$2.76 |
$32.36B |
$3.68B |
11.4% |
| 2025 |
$3.61 |
$33.54B |
$4.66B |
13.9% |
| 2025 |
$3.61 |
$33.54B |
$4.66B |
13.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$5.65 |
$5.57 – $5.71 |
$36.16B |
$36.03B – $36.24B |
8 |
| 2027 |
$6.08 |
$5.99 – $6.24 |
$38.64B |
$37.39B – $39.3B |
15 |
| 2028 |
$6.53 |
$5.84 – $7.15 |
$40.64B |
$40.48B – $40.8B |
9 |
| 2029 |
$7.14 |
$6.89 – $7.28 |
$43.27B |
$42.06B – $43.9B |
3 |
| 2030 |
$7.77 |
$7.49 – $7.92 |
$45.56B |
$44.28B – $46.23B |
3 |
